Repligen (NASDAQ:RGEN) was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating in a note issued to investors on Tuesday.
RGEN has been the topic of a number of other reports. BidaskClub lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. CL King assumed coverage on shares of Repligen in a research report on Monday, November 13th. They set a “buy” rating and a $41.00 target price on the stock. Zacks Investment Research upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. JPMorgan Chase & Co. started coverage on shares of Repligen in a research report on Tuesday, December 5th. They set an “overweight” rating and a $42.00 target price on the stock. Finally, Citigroup started coverage on shares of Repligen in a report on Friday, December 8th. They issued a “buy” rating and a $45.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $44.38.
Repligen (NASDAQ:RGEN) opened at $36.41 on Tuesday. Repligen has a 12-month low of $29.56 and a 12-month high of $46.81. The stock has a market cap of $1,570.49, a P/E ratio of 51.28, a PEG ratio of 2.42 and a beta of 0.94. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.08 and a current ratio of 9.63.
Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.08. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The company had revenue of $41.60 million for the quarter, compared to analyst estimates of $41.13 million. During the same period in the prior year, the business earned $0.08 earnings per share. Repligen’s quarterly revenue was up 62.5% on a year-over-year basis. research analysts anticipate that Repligen will post 0.7 EPS for the current fiscal year.
In related news, Director Thomas F. Ryan, Jr. sold 4,696 shares of the stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $36.16, for a total value of $169,807.36. Following the transaction, the director now directly owns 9,700 shares in the company, valued at $350,752. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Anthony Hunt sold 8,970 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the completion of the sale, the chief executive officer now owns 83,613 shares in the company, valued at $3,005,887.35. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new stake in Repligen in the third quarter worth $3,349,000. Swiss National Bank raised its holdings in Repligen by 5.3% in the fourth quarter. Swiss National Bank now owns 63,700 shares of the biotechnology company’s stock worth $2,311,000 after purchasing an additional 3,200 shares during the period. Cornerstone Capital Management Holdings LLC. raised its holdings in Repligen by 78.0% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 16,206 shares of the biotechnology company’s stock worth $620,000 after purchasing an additional 7,100 shares during the period. Legal & General Group Plc raised its holdings in Repligen by 9.1% in the third quarter. Legal & General Group Plc now owns 74,927 shares of the biotechnology company’s stock worth $2,870,000 after purchasing an additional 6,250 shares during the period. Finally, First Trust Advisors LP raised its holdings in Repligen by 20.2% in the third quarter. First Trust Advisors LP now owns 46,910 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 7,874 shares during the period. Institutional investors own 87.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Repligen (RGEN) Raised to “B-” at TheStreet” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/15/repligen-rgen-raised-to-b-at-thestreet.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.